Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Virtual Reality-Based Cognitive-Motor Rehabilitation in Traumatic Brain Injury

10 de novembro de 2026 atualizado por: Dr. Gabriel Zeilig

Novel Virtual Reality-Based Cognitive-Motor Rehabilitation for Individuals With Traumatic Brain Injury

This study aims to evaluate the feasibility, safety, and efficacy of a novel virtual reality (VR)-based cognitive-motor rehabilitation program for individuals with traumatic brain injury (TBI). The intervention uses the Virtual Reality Color Trails Test (VR-CTT), which combines cognitive tasks with upper-limb movements in an immersive virtual environment.

The study consists of two stages. The first stage is a feasibility pilot involving 15 participants who will complete three VR training sessions over one week. The second stage is a randomized controlled trial involving 80 participants allocated to either VR-CTT training combined with standard rehabilitation or a control group receiving standard rehabilitation with additional therapy time. The intervention will consist of nine sessions over three weeks.

The study will assess feasibility, safety, executive functions, upper-limb motor performance, balance, and functional outcomes.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Traumatic brain injury (TBI) frequently results in cognitive and motor impairments that affect everyday functioning. Conventional rehabilitation often addresses these domains separately, although many daily activities require their simultaneous integration. This study evaluates a rehabilitation approach based on the Virtual Reality Color Trails Test (VR-CTT), an immersive system developed at Sheba Medical Center that combines cognitive challenges with coordinated head and upper-limb movements.

The study consists of two sequential stages.

**Stage 1: Feasibility Pilot**

Fifteen participants with TBI will receive three VR-CTT training sessions over one week in addition to standard rehabilitation. Training will progress from seated tasks to more challenging standing activities according to individual abilities. This stage will assess feasibility, safety, usability, and participant satisfaction to inform implementation of the subsequent trial.

**Stage 2: Randomized Controlled Trial**

Eighty participants with TBI will be randomly assigned in a 1:1 ratio to two parallel groups. The intervention group will receive standard rehabilitation supplemented by nine VR-CTT training sessions over three weeks. Training difficulty will increase progressively through changes in cognitive demands, the number of targets, body position, and unilateral or bilateral hand use.

The control group will receive standard rehabilitation supplemented by additional cognitive or motor therapy to match the total treatment time of the intervention group.

Outcome assessments will be conducted before and after the intervention period and will include measures of executive functioning, upper-limb motor performance, balance, everyday functioning, and cognitive-motor interaction. Outcome assessors will remain blinded to group allocation during the randomized stage.

The study aims to determine whether integrated VR-based cognitive-motor training is feasible and safe and whether it improves cognitive and motor outcomes compared with conventional rehabilitation.

Tipo de estudo

Intervencional

Inscrição (Estimado)

95

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Ramat Gan, Israel
        • Sheba Medical Center
        • Contato:
        • Subinvestigador:
          • Meir Plotnik, Prof.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 50 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

**Inclusion Criteria:**

  1. Men and women aged 18-50 years.
  2. Admitted for inpatient rehabilitation following traumatic brain injury (TBI).
  3. Glasgow Coma Scale (GCS) score of 9-15 at admission.
  4. Brain CT positive for acute intracranial trauma (including complicated mild or moderate TBI).
  5. Presence of cognitive and motor symptoms as determined by clinical evaluation.
  6. Sufficient decision-making capacity to provide informed consent.

**Exclusion Criteria:**

  1. Inability to meaningfully comprehend the study procedures (e.g., severe aphasia or cognitive impairment), as determined through a structured capacity assessment.
  2. Severe physical limitations that prevent the use of VR equipment (e.g., severe upper-limb fractures preventing controller use).
  3. History of epilepsy or seizures triggered by flashing lights.
  4. Severe visual or vestibular impairments that would make VR exposure unsafe (e.g., severe vertigo).
  5. Active psychiatric conditions (e.g., acute psychosis) likely to interfere with adherence to study procedures.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Stage 1: VR-CTT Feasibility Pilot

Fifteen participants with traumatic brain injury will receive standard rehabilitation supplemented by three VR-CTT training sessions over one week. Sessions will last approximately 45 minutes and progress from seated activities to standing activities according to participants' abilities. This stage will evaluate feasibility, safety, and usability.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Experimental: Stage 2: VR-CTT Training

Forty participants will receive standard inpatient rehabilitation supplemented by nine VR-CTT training sessions over three weeks (three sessions per week, approximately 45 minutes each). Training will progressively increase cognitive and motor demands through changes in target number, task complexity, posture, and hand use.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Comparador Ativo: Stage 2: Active Control

Forty participants will receive standard inpatient rehabilitation supplemented by approximately three hours per week of additional cognitive or motor therapy with a therapist or volunteer, without VR-CTT training. The additional therapy is intended to match the total treatment time of the intervention group.

Additional cognitive or motor rehabilitation exercises administered by a therapist or volunteer, supplementing standard inpatient rehabilitation. Participants receive approximately three hours of additional therapy per week over three weeks to match the total treatment time provided to the VR-CTT intervention group.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Executive Function Composite Score
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in executive functioning assessed using a composite score derived from the Stroop Test, Rule Shift Cards Test (BADS), and Montreal Cognitive Assessment (MoCA). Standardized scores will be used to evaluate changes in executive control, including inhibition, cognitive shifting, and mental flexibility.

Baseline (Week 0) and post-intervention (Week 4).
Change in Upper Limb Motor Function (ARAT)
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in upper limb motor function assessed using the Action Research Arm Test (ARAT), which evaluates upper extremity motor performance and coordination. Higher scores indicate better motor function.

Baseline (Week 0) and post-intervention (Week 4).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Functional Status (FSE)
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in everyday functional outcomes assessed using the Functional Status Examination (FSE), which evaluates functional limitations following traumatic brain injury.

Baseline (Week 0) and post-intervention (Week 4).
Change in Balance (Berg Balance Scale)
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in static and dynamic balance assessed using the Berg Balance Scale (BBS). Higher scores indicate better balance performance.

Baseline (Week 0) and post-intervention (Week 4).
Change in Cognitive-Motor Performance (VR Supermarket Task)
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in performance on a virtual reality-based supermarket task assessing cognitive-motor integration, including divided attention and sustained attention during simulated everyday activities.

Baseline (Week 0) and post-intervention (Week 4).
Change in Dual-Task Performance (Box and Block Test)
Prazo: Baseline (Week 0) and post-intervention (Week 4).

Change in dual-task performance assessed using the Dual-Task Box and Block Test (BBT-DT), in which participants transfer blocks while simultaneously performing mental arithmetic.

Baseline (Week 0) and post-intervention (Week 4).
Feasibility of VR-CTT Training
Prazo: During the one-week pilot intervention (Stage 1).

Feasibility assessed by adherence to the planned VR-CTT training protocol, including the proportion of scheduled training sessions completed by participants.

During the one-week pilot intervention (Stage 1).
Simulator Sickness Symptoms
Prazo: After each VR training session during the one-week pilot (Stage 1).

Simulator sickness symptoms, including nausea, dizziness, headache, and eyestrain, assessed after VR training sessions using the Simulator Sickness Questionnaire (SSQ).

After each VR training session during the one-week pilot (Stage 1).
VR-CTT Usability and Participant Satisfaction
Prazo: At completion of the one-week pilot intervention (Stage 1).

Usability and participant satisfaction with the VR-CTT system assessed using post-training feedback questionnaires addressing comfort, ease of use, and overall experience.

At completion of the one-week pilot intervention (Stage 1).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2029

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • SHEBA-26-3045-GZ-CTIL

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .